These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 31394225)

  • 1. Topical Recombinant Human Epidermal Growth Factor for Diabetic Foot Ulcers: A Meta-Analysis of Randomized Controlled Clinical Trials.
    Yang Q; Zhang Y; Yin H; Lu Y
    Ann Vasc Surg; 2020 Jan; 62():442-451. PubMed ID: 31394225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Topical Recombinant Human Epidermal Growth Factor for Treatment of Diabetic Foot Ulcer: A Systematic Review and Meta-Analysis.
    Yang S; Geng Z; Ma K; Sun X; Fu X
    Int J Low Extrem Wounds; 2016 Jun; 15(2):120-5. PubMed ID: 27151755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal Growth Factor is Effective in the Treatment of Diabetic Foot Ulcers: Meta-Analysis and Systematic Review.
    Bui TQ; Bui QVP; Németh D; Hegyi P; Szakács Z; Rumbus Z; Tóth B; Emri G; Párniczky A; Sarlós P; Varga O
    Int J Environ Res Public Health; 2019 Jul; 16(14):. PubMed ID: 31331038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of recombinant human epidermal growth factor for diabetic foot ulcers: A systematic review and meta-analysis of randomised controlled trials.
    Zhao DY; Su YN; Li YH; Yu TQ; Li J; Tu CQ
    Int Wound J; 2020 Aug; 17(4):1062-1073. PubMed ID: 32343054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical epidermal growth factor spray for the treatment of chronic diabetic foot ulcers: A phase III multicenter, double-blind, randomized, placebo-controlled trial.
    Park KH; Han SH; Hong JP; Han SK; Lee DH; Kim BS; Ahn JH; Lee JW
    Diabetes Res Clin Pract; 2018 Aug; 142():335-344. PubMed ID: 29902542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of intralesional recombinant human epidermal growth factor in diabetic foot ulcers in Mexican patients: a randomized double-blinded controlled trial.
    Gomez-Villa R; Aguilar-Rebolledo F; Lozano-Platonoff A; Teran-Soto JM; Fabian-Victoriano MR; Kresch-Tronik NS; Garrido-Espíndola X; Garcia-Solis A; Bondani-Guasti A; Bierzwinsky-Sneider G; Contreras-Ruiz J
    Wound Repair Regen; 2014; 22(4):497-503. PubMed ID: 25041620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth factors for diabetic foot ulcers: mixed treatment comparison analysis of randomized clinical trials.
    Sridharan K; Sivaramakrishnan G
    Br J Clin Pharmacol; 2018 Mar; 84(3):434-444. PubMed ID: 29148070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor in the treatment of diabetic foot ulcers: an update.
    Tiaka EK; Papanas N; Manolakis AC; Georgiadis GS
    Perspect Vasc Surg Endovasc Ther; 2012 Mar; 24(1):37-44. PubMed ID: 22494968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation.
    Fernández-Montequín JI; Infante-Cristiá E; Valenzuela-Silva C; Franco-Pérez N; Savigne-Gutierrez W; Artaza-Sanz H; Morejón-Vega L; González-Benavides C; Eliseo-Musenden O; García-Iglesias E; Berlanga-Acosta J; Silva-Rodríguez R; Betancourt BY; López-Saura PA;
    Int Wound J; 2007 Dec; 4(4):333-43. PubMed ID: 17953679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study.
    Fernández-Montequín JI; Valenzuela-Silva CM; Díaz OG; Savigne W; Sancho-Soutelo N; Rivero-Fernández F; Sánchez-Penton P; Morejón-Vega L; Artaza-Sanz H; García-Herrera A; González-Benavides C; Hernández-Cañete CM; Vázquez-Proenza A; Berlanga-Acosta J; López-Saura PA;
    Int Wound J; 2009 Dec; 6(6):432-43. PubMed ID: 20051095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Long-Term Outcomes Following the Application of Intralesional Epidermal Growth Factor in Patients With Diabetic Foot Ulcers.
    Kahraman M; Misir A; Kizkapan TB; Ozcamdalli M; Uzun E; Mutlu M
    J Foot Ankle Surg; 2019 Mar; 58(2):282-287. PubMed ID: 30612874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydrogel dressings for healing diabetic foot ulcers.
    Dumville JC; O'Meara S; Deshpande S; Speak K
    Cochrane Database Syst Rev; 2011 Sep; (9):CD009101. PubMed ID: 21901730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration.
    O'Meara S; Cullum N; Majid M; Sheldon T
    Health Technol Assess; 2000; 4(21):1-237. PubMed ID: 11074391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intralesional and perilesional application of an epidermal growth factor (Heberprot-P®) in diabetic foot ulcers. Part one.
    Montequin JF; Bonachea LS; Acosta JB; Peres CV; Gutierres WS; Duarte GA
    Angiol Sosud Khir; 2018; 24(4):33-42. PubMed ID: 30531767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving Diabetic Wound-Healing Outcomes With Topical Growth Factor Therapies.
    Wong AYW; Hooi NMF; Yeo BSY; Sultana R; Bee YM; Lee ARYB; Tay SM
    J Clin Endocrinol Metab; 2024 Jul; 109(8):e1642-e1651. PubMed ID: 38477463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical platelet-derived growth factor vs placebo therapy of diabetic foot ulcers offloaded with windowed casts: a randomized, controlled trial.
    Ma C; Hernandez MA; Kirkpatrick VE; Liang LJ; Nouvong AL; Gordon II
    Wounds; 2015 Apr; 27(4):83-91. PubMed ID: 25855851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor outperforms placebo in the treatment of diabetic foot ulcer: a meta-analysis.
    Rahim F; Yan X; Shah JA; Bibi N; Khan ZU; Nawaz S; Ming Y
    F1000Res; 2022; 11():773. PubMed ID: 37867626
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of intralesional recombinant human epidermal growth factor in chronic diabetic foot ulcers.
    Dumantepe M; Fazliogullari O; Seren M; Uyar I; Basar F
    Growth Factors; 2015 Apr; 33(2):128-32. PubMed ID: 25856197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silver based wound dressings and topical agents for treating diabetic foot ulcers.
    Bergin SM; Wraight P
    Cochrane Database Syst Rev; 2006 Jan; (1):CD005082. PubMed ID: 16437516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulation response and partial wound closure predict healing in clinical trials on advanced diabetes foot ulcers treated with recombinant human epidermal growth factor.
    Valenzuela-Silva CM; Tuero-Iglesias ÁD; García-Iglesias E; González-Díaz O; Del Río-Martín A; Yera Alos IB; Fernández-Montequín JI; López-Saura PA
    Diabetes Care; 2013 Feb; 36(2):210-5. PubMed ID: 22966096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.